Professor Augusto Pessina Brief CV
Present Position
Associated Professor Professor of Microbiology Faculty of Medicine of the University of Milan.
Head of Cell Culture Laboratory ,Section of Microbiology, Department of Biomedical Surgical
and Dental Sciences.President Gruppo Italiano Staminali Mesenchimali (GISM).Past President:
Associazione Italiana di Colture Cellulari (AICC)
Teaching and research:
Graduated in Biological Science,University of Milan (1971). Specialized in Medical
Microbiology, University of Milan (1978).Assistant Researcher at Centre of Cellular Pathology
of the National Council for Research, Milan (1973-1976).Selected as Italian Participant to the
“Second training course on experimental cancer research of UICC (Amsterdam,1975).Appointed
by the National Board of Education of Italy to the Department of Pathology, Hospital of Desio for
studying the effect of Dioxine (TCDD) on immune system of children accidentally exposed to the
toxic in Seveso (1976-1981).
Professor of General Pathology at School of Pharmacology, Faculty of Pharmacy, University of
Milan.(1982-1985). Appointment by the Board of Education to the Institute of Medical
Microbiology, University of Milan for developing new educational training (1981-1988).
External Examiner for PhD thesis at the School of Biological Sciences, National Cell and Tissue
Culture Centre Dublin City University (Ireland) (1994,2011).Reporter of a PhD thesis at the
Universitè de Bretagne Occidentale (UBO) France(2004).
Management of scientific events
Organizer and promoter of many national and international scientific events as congress, meeting,
workshop and courses.Co-organizer with Prof. Martin Clynes ( Dublin City University-Ireland) of
the "First International Meeting on Drug Resistance in Cancer" (1995).Representative of the
division "Cancer sensitivity and drug resistance" of the European Tissue Culture Society (ETCS)
(1994-1998). Chairman of the Italian Committee of the “3rd World Congress on Alternatives and
Animal use in life science”. Bologna 1999.Member of the Scientific Advisory Board of the National
Institute for Cellular Biotechnology (NICB) of Dublin City University ( Ireland) (2001-2005).CoPresident of the 46PthP ETCS meeting held in Verona ( 2006).President of the Italian Association
for Cell Culture (AICC) ( 2007-2010).Member of the International Scientific Societies and peer
reviewer of may international scientific journals.
Scientific responsible of the following European Commission projects:
“In vitro system for testing haematotoxicity”(1994-1996).“Inhibition of CFU-E/BFU-E by different
classes of chemicals: a comparative study on direct effects on progenitors and the effect on longterm exposure of bone marrow”(1997-1998). “In vitro tests for haematotoxicity: prevalidation and
validation of GM-CFU assay for predicting acute neutropenia”(1997-2001).“Development and
prevalidation of the in vitro assays for the prediction of thrombocytopenia” (Italian Operative Unit
2000-2002)“Purification and regulation of haematopoietic stem cells: in vitro studies”(20012002)."Plasticity of adult stem cells in cord blood" (2002-2003)“Prevalidation of rat CFU-GM
assay”( 2006-2008)
Scientific Unit Responsible inside the projects
“Transplant of adult stem cells in regenerative cellular therapy” of Blood Plan of Regione Lombardia (
2006-2008). “Role of human mesenchymal stem cells in tumor angiogenesis” of AIRC ( Associazione
Italiana per la Ricerca sul Cancro) ( 2010-2012).“LoCMeD - Lab on Chip for testing Myelotoxic effect of
Drugs and chemicals” (Fund from Fondazione Cariplo) (2011-2013). " Mesenchymal stromal cells loaded
with Paclitaxel home glioblastoma vasculature and inhibit tumor growth” of AIRC ( Associazione Italiana
per la Ricerca sul Cancro) ( 2013-2016)
Some notes on research activity particularly related to hematotoxicity
The experience of Dr Augusto Pessina in the field of hematotoxicity originated in the years 1970 with
studies concerning the relation between the neoplastic growth and the haematopoietic disorders observed in
tumor bearing mice. He developed specific “in vitro” techniques for studying the effect exerted by factors
produced by tumor cells on the proliferation and differentiation of myeloid precursors and in his laboratory
were isolated cytokines active on the haematopoietic progenitors (Int. J. Immunopharmacol. 7,549,1985;
Blut,55,499,1987).
At the first UICC training course organized in Amsterdam on 1975 had as teacher Donald Melcalf
(who is considered the pioneer of the “in vitro” studies on proliferation and differentiation of haematopoietic
progenitors) and the possibility to improve the techniques for assessing the "in vitro" growth of granulocytemacrophage committed cells (GM-CFU).
Dr. Pessina has been involved five years (1976-1981)in an international project at the Hospital of
Desio (Milan ,Italy) for studying the haematotoxic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on
the immune system of children accidentally exposed to the toxic in the area of Seveso ( ICMESA accident).
Since 1981 he runs a Laboratory of Cell Culture at the Institute of Microbiology (Milan) and his
researches have been continued on the relationship between tumor growth and the production of cytokines
( CSFs) involved in the proliferation- differentiation of pluripotent stem cells ( CFU-s) and committed
progenitors ( CFU-C) in haematopoiesis ( J. Cancer Res.Clin. Oncol.,102,235,1982; Oncology 39,391,1982;
J.Natl.Cancer Inst.,¸76,1095,1986).
In his laboratory have been established twi new cell lines: a stromal cell line obtained from murine
bone marrow adherent cells (SR-4987) , ( Cytotechnology 8,93,1992 ) available by ATCC (CRL-2028) and a
subclone of WEHI-3B leukemia cells resistant to ciprofloxacin ( Cancer J.,6,291,1993) due to a mutation of
topoisomerase II.
By using SR-4987 cells has been standardized a new "in vitro" method for testing FGFs in biological
samples and developed an “in vitro” model to investigate the role of stromal cells in the modulation of drug
induced hematotoxicity (Life Sci.,65,513,1999).
Researches of the response of different cellular models the biological effects of microbial toxins
demonstrated that the proliferative block exerted by Cholera Toxin may be dependent or not to the cAMP
accumulation and that there are membrane ganglioside with different affinity to CT ad capacity to transduce
the signal. A stable mutant of a leukemia cell line (WEHI-3B) has been established by Dr Pessina which
lacks of the Gal-GalNac-GM1b ganglioside that is a very important functional receptor in WEHI-3b cells (
Cell .Mol.Biol.,44,933-940,1998. Mol.Cell.Biochem,152,103-112,1995 Mol.Cell Biochem. 233,19-26, 2002)
By using GM-CFU techniques Dr Pessina studied the effect of topoisomerase inhibitors, antibiotics and
microbial toxins on different animal cell models ( J.Antimicrob. Chemother., 24,203,1989; Biochim .Bioph.
Acta,1013,206,1989 ; Mol. Cell Biochem.,152,1995).
Since 1994 he managed EC contracts concerning the development of alternative methods for
hematototoxicity testing and coordinated projects of prevalidation and validation of standard operating
procedure based on the use of multipotent stem cells as progenitors of granulocyte-macrophages (GMCFU) , megakaryocytes (Mk-CFU) and erythrocytes (CFU-E).
Based on these results ( Toxicological Sciences , 75,355-367,2003 ) the ECVAM Scientific Advisory
Committee (ESAC) on 2006 unanimously endorsed the CFU-GM assay for predicting acute neutropenia in
humans. Recently a study has been conducted to prevalidate the GM-CFU assay with frozen bone
marrow cells of rat that can contribute to REACH programme ( Altern.To Lab.Animals 37: 417-425,2009.
Altern.To Lab.Animals 38:105-117,2010).
Since 2004 the cell culture laboratory of Dr Pessina is involved in studies on the therapeutic potential of
stem cells and on assays to assess their safety with a particular attention to the microbiological risks
(BBRC, 323:315-322,2004, Crit.Rev.Microbiol, 34:1-12,2008,Transpl Infect Dis .11 : 491-496,2009 ;,Cell
Biol. Int. 34:783-790,2010). More recent his group have indicated that MSCs can be used as drug
carrier. By using a cancer drug ( Paclitaxel) has been demonstrated that human MSCs are able to
uptake and release the drug and that PTX loaded MSCs produced a dramatic inhibition of tumor
growth both in vitro and in vivo. PLoS ONE 6(12): e28321. doi:10.1371/journal.pone.0028321. In recent
paper his laboratori demonstrated that drugs can be released by mesenchymal stem cells into
microvesicles/exosomes opening new possible biotechnology application for the production of more
bioavailable molecules able to support new therapeutic approaches.
A selection of some publications of the last 15 years 1999-2014.
2014-2010
PASCUCCI L, COCCÈ V, BONOMI A, AMI D, CECCARELLI P, CIUSANI E, VIGANÒ L,
LOCATELLI A, SISTO F, DOGLIA SM, PARATI E, BERNARDO ME, MURACA M,
ALESSANDRI G, BONDIOLOTTI G, PESSINA A. Paclitaxel is incorporated by mesenchymal
stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug
delivery. Journal Controlled Release 192: 262-270, 2014.
SISTO F, BONOMI A, CAVICCHINI L, COCCÈ V, SCALTRITO MM, BONDIOLOTTI G,
ALESSANDRI G, PARATI E, PESSINA A. Human mesenchymal stromal cells can uptake and
release ciprofloxacin, acquiring in vitro anti-bacterial activity. Cytotherapy. 2014 ,16:181-90.
MARIOTTI M, COLOGNATO R, RIMOLDI M, RIZZETTO M, SISTO F, COCCE V, BONOMI
A, PARATI E, ALESSANDRI G, BAGNATI R, PESSINA A. Mesenchymal Stromal Cells Uptake
And Release Paclitaxel Without Reducing Its Anticancer Activity. ANTI-CANCER AGENTS IN
MEDICINAL
CHEMISTRY,
vol.
13,
p.
523-530,
ISSN:
1871-5206,
doi:
10.2174/1871520611313030015
S. NAVONE, L. PASCUCCI, M. DOSSENA, A. FERRI, G. INVERNICI, F. ACERBI, S.
CRISTINI, G. BEDINI, V. TOSETTI, V. CESERANI, A. BONOMI, A. PESSINA, G. FREDDI,
A. ALESSANDRINO, P. CECCARELLI, R. CAMPANELLA, G. MARFIA, G. ALESSANDRI,
E.A. PARATI (2014). Decellularized silk fibroin scaffold primed with adipose mesenchymal
stromal cells improves wound healing in diabetic mice. STEM CELL RESEARCH & THERAPY,
vol. 5, p. 1-15, ISSN: 1757-6512, doi: 10.1186/scrt396
ANTONELLA CONFORTI, SIMONE BIAGINI, NADIA STARC, ALESSANDRA PROIA,AUGUSTO
PESSINA, GIULIO ALESSANDRI, FRANCO LOCATELLI,
MARIA ESTER BERNARDO. Human mesenchymal stromal cells primed with paclitaxel, apart from
displaying anti-tumor activity, maintain their immune regulatory
functions in vitro. Cytotherapy, 2014; 16: 868e870
pen Access
LUIGI BALDUCCI, ANTONELLA BLASI, MARILISA SALDARELLI, ANTONIO SOLETI, AUGUSTO
PESSINA, ARIANNA BONOMI,VALENTINA COCCÈ, MARTA DOSSENA, VALENTINA TOSETTI,
VALENTINA CESERANI, STEFANIA ELENA NAVONE,MARIA LAURA FALCHETTI, EUGENIO
AGOSTINO PARATI AND GIULIO ALESSANDRI. Immortalization of human adipose-derivedstromal
cells: production of cell lines with highgrowth rate, mesenchymal marker expression andcapability to secrete
high levels of angiogenic factors. Stem Cell Research & Therapy 2014, 5:63
M. RASPONI, A. GAZANEO, A. BONOMI, P. OCCHETTA, L. CAVICCHINI, V. COCCE, G. B. FIORE,
A.PESSINA AND A. REDAELLI. Lab-on-Chip for testing Myelotoxic effect of drugs and chemicals
GNB2014, June 25th-27th 2014, Pavia, Italy.
PESSINA A, COCCÈ V, PASCUCCI L, BONOMI A, CAVICCHINI L, SISTO F, FERRARI M,
CIUSANI E, CROVACE A, FALCHETTI ML, ZICARI S, CARUSO A, NAVONE S, MARFIA
G, BENETTI A, CECCARELLI P, PARATI E, ALESSANDRI G. Mesenchymal stromal cells
primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of
leukaemia-bearing mice. Br J Haematol. 2013; 160: 766-78.
BONOMI A, COCCÈ V, CAVICCHINI L, SISTO F, DOSSENA M, BALZARINI P,
PORTOLANI N, CIUSANI E, PARATI E, ALESSANDRI G, PESSINA A. Adipose-tissue-
derived stromal cells primed in vitro with paclitaxel acquires anti-tumor activity. Int J
Immunopathol Pharmacol. 2013:26,33-41.
PESSINA A, BONOMI A, CIUSANI E, PASCUCCI L, PARATI E, ALESSANDRI G. Mesenchymal
stromal cells used for carrying and delivering Paclitaxel in “Paclitaxel: Biosynthesis, Mechanisms of Action
and Clinical Uses ”, D. Morales, Nova Science Publishers 2013, pp 141-157.
PESSINA A , BONOMI A, PARATI E, PALLINI R, ALESSANDRI G. Primed mesenchymal
stromal cells for cancer therapy. In “Stem Cell Therapeutics for Cancer”. Ed Khalid Shah, Wiley
Blackwell 2013, pp 189-204.
LAURA DE GIROLAMO, ENRICO LUCARELLI2, GIULIO ALESSANDRI3, MARIA ANTONIETTA
AVANZINI4, MARIA ESTER BERNARDO,ETTORE BIAGI, ANNA TERESA BRINI, GIOVANNA
D’AMICO, FRANCA FAGIOLI, IVANA FERRERO10, FRANCO LOCATELLI,RITA MACCARIO,
MARIO MARAZZI, ORNELLA PAROLINI, AUGUSTO PESSINA AND MARIA LUISA TORRE.
Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm.Efficacy and Critical Aspects in Cell
Therapy. Current Pharmaceutical Design, 2013, 19, 2459-2473
S. DUCHI, P. DAMBRUOSO,E. MARTELLA,G. SOTGIU,A. GUERRINI, E. LUCARELLI,A.
PESSINA,V. COCCÈ,A. BONOMI,AND G. VARCHI.
Thiophene-Based Compounds as Fluorescent Tags to Study Mesenchymal Stem Cell Uptake and Release of
Taxanes BIOCONJUGATE CHEMISTRY, vol. 25, p. 649-655, ISSN: 1043-1802, doi:
10.1021/bc5000498
AUGUSTO PESSINA,VALENTINA COCCÈ, ARIANNA BONOMI, LOREDANA CAVICCHINI,
FRANCESCA SISTO, MAURA FERRARI,EMILIO CIUSANI, STEFANIA NAVONE, GIOVANNI
MARFIA, EUGENIO PARATI AND GIULIO ALESSANDRI. Human Skin-Derived Fibroblasts Acquire In
Vitro Anti-Tumor Potential after Priming with Paclitaxel .Anti-Cancer Agents in Medicinal Chemistry, 2013,
13, 523-30.
PESSINA A.,SISTO F.,COCCE’ V.,CAVICCHINI L.,CIUSANI E.,GRIBALDO L., BONOMI . A
mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into Osteoblast-like
cells. Cell Biol Toxicol 27:169-180,2011.
PESSINA A., BONOMI A, COCCÈ V, INVERNICI G, NAVONE S, CAVICCHINI L et al. . Mesenchymal
Stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE 6(12):
e28321.doi:10.1371/journal.pone.0028321 (2011).
PESSINA A.,BONOMI A.,CAVICCHINI L.,ALBELLA B., CERRATO L.,PARENT-MASSIN D.,SIBIRIL
Y.,PARCHMENT R.,BEHRSING H.,VERDERIO P., PIZZAMIGLIO S.,GIANGRECO M., BAGLIO
C.,COCCÈ V.,SISTO F. and GRIBALDO L..Prevalidation of Rat GM-CFU Assay for In Vitro Toxicology
Application. Altern.To Lab.Animals (ATLA) 38:105-117,2010.
PESSINA A., BONOMI A.,SISTO F., BAGLIO C., CAVICCHINI L.,CIUSANI L.,COCCÉ V.,
GRIBALDO L.. CD45+/CD133+ positive cells expanded from umbilical cord blood expressing pdx-1 and
markers of pluripotency. Cell Biol. Int. 34:783-790,2010.
PESSINA A. Cellule staminali pluripotenti . Le prospettive delle iPSC restano problematiche
Emmeciquadro 38: 27-30,2010.
PESSINA A., BONOMI A. Prediction of potential drug myelotoxicity by in vitro assays
on haematopoietic progenitors. In Methods in Bioengineering: Alternative technologies to
animal testing" eds Tim Maguire and Eric Novik Eds,Artech House Boston-London. Pages
115-131 ,2010 .
LULLI M, DI GESUALDO F.,WITORT E.,PESSINA A.,CAPACCIOLI S.. Cell death:
physiopathological and therapeutic implications. Cell Death Dis. 1: e30; doi: 10.1038/cddis.2010.
2009-2005
PESSINA A.,PARENT-MASSIN D., ALBELLA B.,VAN DEN HEUVEL R.,CASATI
S.,CROERA C.,MALERBA I.,SIBIRIL Y.,GOMEZ.S., DE SMEDT.,GRIBALDO L..
Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs.
Toxicology in Vitro, 23:194-200,2009.
PESSINA A., BONOMI A., BAGLIO C., CAVICCHINI L., GRIBALDO Refinement and
Optimisation of the rat CFU-GM assay to use cryopreserved bone marrow cells for “in vitro” toxicology
application . Altern.To Lab.Animals (ATLA) 37: 417-425,2009.
PESSINA A.,BONOMI A.,COCCÈ V., BERNARDO M.E., COMETA A.M., FERRARI M., SISTO
F.,CAVICCHINI L.,LOCATELLI F. Assessment of human herpesvirus-6 infection in mesenchymal stromal
cells ex vivo expanded for clinical use.Transpl Infect DisT.11 : 491-496,2009 .
PESSINA A. BONOMI A., BAGLIO C.,CAVICCHINI L.,SISTO F., NERI MG.,GRIBALDO
L..Microbiological Risk Assessment In Stem Cell Manipulation. Crit.Rev.Microbiol, 34:1-12,2008
PESSINA A., BONOMI A.,CASATI S.,COLLOTTA A.,CROERA C.,MARAFANTE
E.,PALITTI F.,GRIBALDO L.. Mitochondrial function, apoptosis and cell-cycle delay in the WEHI-3B
leukemia cell line and its variant ciprofloxacin-resistant WEHI-3B/CPX .
Cell Prolif.,40,568-579,2007.
PESSINA A., BONOMI A. CFU-GM assay for evaluation of drug Myelotoxic Activity
Curr.Prot.Toxicol. 34:20.2.1-20.2.18, Eds. John Wiley & Sons,Inc., 2007.
PESSINA A., TURLIZZI E., BONOMI A., GUIZZARDI F., CAVICCHINI L.,CROERA C., BAREGGI
S..In vitro toxicity of clozapine,olanzapine and quetiapine on granulocyte-macrophage progenitors(GMCFU). Pharmacopsychiatry,39,20-22,2006.
PESSINA A., CROERA C.,SAVALLI N.,BONOMI A.,CAVICCHINI L.P1P,TURLIZZI E., GUIZZARDI
F.,GUIDO L.,DAPRAI L.,P1P NERI MG..Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to
Cholera Toxin (CT)-induced apoptosis. Cell Res. 16:306-312,2006
PESSINA A., and GRIBALDO L..The key role of adult stem cells: therapeutic perspectives. Curr. Med.
Res. Opin.,22,2287-2300,2006
PESSINA A., MALERBA I., GRIBALDO L. Haematotoxicity testing by cell clonogenic assay in drug
development and preclinical trials Curr.Pharmaceut.Design 11,1055-1065,2005.
1999-2004
PESSINA A., CROERA C., BAYO M., MALERBA I., PASSARDI L., CAVICCHINI L.,
NERI M.G., GRIBALDO L. A methylcellulose microculture assay for the in vitro assessment of drug
toxicity on granulocyte- macrophage progenitors (CFU-GM). ATLA 32:17-23, 2004
PESSINA A.,ELETTI B.,CROERA C.,SAVALLI N.,DIODOVICH C.,GRIBALDO L..
Pancreas developing markers expressed on human mononucleated umbilical cord blood cells.Biochem
Biophys. Res. Comm. 323:315-322,2004
PESSINA A., ALBELLA B. , BAYO M., BUEREN J.,.BRANTOM P., CASATI S.,.
CROERA C.,GAGLIARDI G FOTI P, PARCHMENT R., PARENT-MASSIN D.,
SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL R.,.GRIBALDO L.
Application of the CFU-GM assay to predict acute drug-induced neutropenia:an international blind trial to
validate a prediction model for the maximum tolerated dose(MTD) of myelosuppressive xenobiotics.
Toxicological Sciences , 75,355-367,2003 .
ROSEEUW E.,COESSENS V.,BALAZUC AM.,LAGRANDERIE M.,CHAVAROT P.,
PESSINA A., NERI MG., SCHACHT E.,MARCHAL G., DOMURADO D..
Synthesis, degradation and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin.
Antimicrob. Agents Chemother.,47,3435-3441,2003.
PESSINA A., BAYO M.,CROERA C.,MERINGOLO F.,NERI MG.MONTESISSA L.,
RAIMONDI A. In vitro sensitivity of Human Gastric Cancer Cells( HGC-27) to Helicobacter pylori
cytotoxin. Scand. J. Gastroenterol. 12:1228-1234,2003.
PESSINA A., GIULIANI A., CROERA C., FOTI P., MASCOLO L. GAGLIARDI G. NERI MG.
Selection of a WEHI-3B leukemia cell subclone resistant to inhibition by cholera toxin. Mol.Cell Biochem.,
233,19-26,2002.
PESSINA A., GAGLIARDI G.,CROERA C.FOTI P.,DASSI C.BRAMBILLA P.,NERI MG..Secretion of
basic fibroblast growth factor (FGF-2) by WEHI-3B myelomonocitic leukemia cells. Growth Factors ,
20,121-129,2002.
PESSINA A.,RAIMONDI A:;CROERA C:, ACCHINI M:,MINEO E.,FOTI P:,NERI MG: Altered DNA
cleavage activity of topoisomerase II from WEHI-3B leukemia cells resistant to ciprofloxacin. Anti-Cancer
Drugs,12, 441-451,2001
PESSINA A,RAIMONDI A.CERRI A. PICCIRILLO M, NERI MG, CROERA C. ,FOTI P.,BERTI E.
High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors. Cell
Proliferation ,34,243-252,2001.
PESSINA A., ALBELLA B. , BUEREN J.,.BRANTOM P., CASATI S.,.CROERA C., GAGLIARDI G.,
GRIBALDO L, FOTI P., PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN
DEN HEUVEL Prevalidation of a model for predicting acute neutropenia by Colony Forming UnitGranulocyte/Macrophage CFU-GM) assay Toxicology in Vitro, 15,729-740,2001.
GRIBALDO L, MALERBA I.,COLLOTTA A.,CASTI S.,PESSINA A.. Inhibition of CFGU-e/BFU-E by
3’-azido- 3’-deoxythymidine,chlorpropamide and protoporphirin IX zinc (II): a comparison between direct
exposure of progenitor cells and long-term exposure of bone marrow. Toxicological Sciences 58, 96101,2000.
PESSINA A.,PICCIRILLO M.,MINEO E.,CATALANI P.,GRIBALDO L., MARAFANTE E., NERI
MG.,RAIMONDI A. Role of SR-4987 stromal cells in the modulation of Doxorubicin toxicity to in vitro
granulocyte-macrophage progenitors (GM-CFU). Life Sciences, 65,513-523,1999.
PESSINA A., ROSSONI L.,PICCIRILLO M.,SALA G.,NERI MG.. Preliminary study on in vitro activity
and cytotoxicity on cell cultures of a new polyene antifungal molecule (SPA-S-843). Eur. J. Pharmac.
Biopharmac. 47,179-184,1999.
GRIBALDO L.,CASATI S.,CASTOLDI A., PESSINA A.Comparison of In Vitro drug sensitivity
of Human Granulocyte-Macrophage progenitors from two different origins:umbilical cord blood
and bone marrow. Exp. Hematol., 27,1593-1598,1999.